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Albumin-induced apoptosis of tubular cells is
modulated by BASP1
MD Sanchez-Niño*,1,2, B Fernandez-Fernandez2,3, MV Perez-Gomez2,3, J Poveda2,3, AB Sanz2,3, P Cannata-Ortiz2,3, M Ruiz-Ortega2,3,
J Egido3, R Selgas1,2 and A Ortiz*,2,3
Albuminuria promotes tubular injury and cell death, and is associated with faster progression of chronic kidney disease (CKD) to
end-stage renal disease. However, the molecular mechanisms regulating tubular cell death in response to albuminuria are not fully
understood. Brain abundant signal protein 1 (BASP1) was recently shown to mediate glucose-induced apoptosis in tubular cells.
We have studied the role of BASP1 in albumin-induced tubular cell death. BASP1 expression was studied in experimental
puromycin aminonucleoside-induced nephrotic syndrome in rats and in human nephrotic syndrome. The role of BASP1 in
albumin-induced apoptosis was studied in cultured human HK2 proximal tubular epithelial cells. Puromycin aminonucleoside
induced proteinuria and increased total kidney BASP1 mRNA and protein expression. Immunohistochemistry localized the
increased BASP1 to tubular cells. BASP1 expression colocalized with deoxynucleotidyl-transferase-mediated dUTP nick-end
labeling staining for apoptotic cells. Increased tubular BASP1 expression was observed in human proteinuric nephropathy by
immunohistochemistry, providing evidence for potential clinical relevance. In cultured tubular cells, albumin induced apoptosis
and increased BASP1 mRNA and protein expression at 6–48 h. Confocal microscopy localized the increased BASP1 expression
in albumin-treated cells mainly to the perinuclear area. A peripheral location near the cell membrane was more conspicuous in
albumin-treated apoptotic cells, where it colocalized with actin. Inhibition of BASP1 expression by a BASP1 siRNA protected from
albumin-induced apoptosis. In conclusion, albumin-induced apoptosis in tubular cells is BASP1-dependent. This information may
be used to design novel therapeutic approaches to slow CKD progression based on protection of tubular cells from the adverse
consequences of albuminuria.
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Chronic kidney disease (CKD) is associated with adverse
patient outcomes, either as a consequence of increased
cardiovascular mortality or of progression to end-stage renal
disease.1 Proteinuria in CKD is mainly composed of albumin.
Pathological albuminuria is now used for CKD risk stratifica-
tion, because it is associated both with increased cardiovas-
cular mortality and accelerated progression of CKD.2,3 In fact,
the only known nephroprotective drugs that slow CKD
progression are anti-proteinuric drugs. However, current anti-
proteinuric strategies may have adverse effects that limit their
protein-lowering and nephroprotective potential.4 Further-
more, residual albuminuria in patients already treated with
anti-proteinuric drugs is still associated with worse outcomes.
A better understanding of the molecular mechanisms linking
albuminuria to CKD progression may offer the chance to
develop novel nephroprotective strategies. In this regard,
albuminuria and tubulointerstitial injury are among the key
outcome indicators in glomerular diseases and evidence
suggests a role of albuminuria in promoting tubular injury and
subsequent interstitial inflammation and fibrosis.3,5–7 Cell
culture and animal models have identified several deleterious
effects of albuminuria or albumin on kidney tubular epithelial
cells.8–14 Animal models of albuminuria resulting from albumin
overload are associated with tubular cell death and tubuloin-
terstitial inflammation and eventual fibrosis.15,16 Numerous
cell culture studies have described a pro-apoptotic and pro-
inflammatory role of albumin on tubular epithelial cells.10–14
PKC-delta activation, oxidative stress, endoplasmic reticulum
stress and caspase-8 activation have been described as
potential mechanisms mediating albumin-induced apoptosis.
However, the molecular mechanisms regulating tubular cell
death in response to albuminuria are not fully understood.
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Apoptosis is an active response to an altered microenviron-
ment characterized by the activation of specific intracellular
lethal pathways.17 The presence of injurious factors and/or the
lack of survival factors may activate the apoptotic molecular
machinery. The involvement of specific molecules that are
activated or suppressed allows the design of therapeutic
strategies that modulate the expression or activity of apoptosis
regulatory factors.18 Brain-abundant, membrane-attached
signal protein 1 (BASP1) was recently characterized as an
intracellular proapoptotic factor that was required for high
glucose-induced apoptosis in kidney proximal tubular cells.19
BASP1 is a 23-kDa myristoylated protein originally isolated
from brain extracts20,21 that shares 70% homology in human
and rat.22 A transcriptomics approach disclosed that BASP1
expression was increased in human diabetic nephropathy
tubulointerstitium.19 Immunohistochemistry localized the
increased BASP1 expression to tubular cells both in humans
and in experimental diabetes. Interestingly, not all tubules
were BASP1-positive: there were BASP1-positive and
BASP1-negative tubules within the same diabetic nephro-
pathy biopsy. Cell culture studies identified a high glucose
concentration as an inducer of BASP1 expression and
BASP1-dependent apoptosis. However, this cell culture
observation does not explain the patchy distribution of
BASP1-expressing tubules in human diabetic kidney, as all
tubules would have been exposed to the same high glucose
concentrations. As albumin induces apoptosis in cultured
tubular cells,10–12 we hypothesized that albumin could be an
inducer of BASP1 expression in tubular cells. This hypothesis
might explain the observation of BASP1-positive and -nega-
tive tubules in human diabetic nephropathy and experimental
diabetic and hypertensive nephropathies.19 Tubules belonging
to a nephron where podocyte injury has resulted in glomer-
uloesclerosis andmore severe albuminuriawould be expected
to expressmore BASP1 than tubules from nephronswith more
preserved functional podocytes. To explore this hypothesis,
we used cell culture and non-diabetic albuminuria models. We
now report that albumin induces Basp1 expression in cultured
proximal tubular cells and in tubular cells in vivo and that
targeting Basp1 protects tubular cells from albumin-induced
apoptosis. This information may be used to protect the
tubulointerstitium from structural damage in proteinuric kidney
diseases with residual albuminuria despite anti-proteinuric
therapy.
Results
PAN induces nephrotic syndrome and BASP1 expression
in the rat kidney. Systemic puromycin aminonucleoside
(PAN) administration causes podocyte injury in rats leading to
an increased urinary protein excretion at day 2 and full-blown
nephrotic syndrome characterized by severe albuminuria
(Figure 1a), hypoalbuminemia, hypercholesterolemia and
ascites at day 10. Increased whole-kidney BASP1 mRNA
(Figure 1b) and protein (Figure 1c) expression was noted 2
and 10 days post PAN injection, coinciding onset and
progression to severe albuminuria. BASP1 protein was
localized diffusely to tubular epithelial cells by immunohis-
tochemistry (Figure 1d). Furthermore, tubular cell BASP1
expression colocalized with deoxynucleotidyl-transferase-
mediated dUTP nick-end labeling-positive cells, indicating
expression of BASP1 by tubular cells undergoing apoptosis
(Figure 2).
Increased BASP1 expression in human proteinuric
nephropathy. In human proteinuric nephropathy, immuno-
histochemistry identified BASP1-positive tubular cells
(Figure 3). Minimal BASP1 staining was observed in tubules
from control kidney samples.
Tubular cell death induced by albumin has features of
apoptosis. Under physiological conditions, proximal tubular
cells reabsorb the minimal amounts of albumin that may get
through the glomerular filtration barrier. The combination of
albumin retention in plasma by the glomerular filtration barrier
and proximal tubular cell reabsorption results in minimal
(o30mg per day in humans) physiological albuminuria.
However, glomerular injury may be associated with filtration
of massive amounts of albumin into the tubular lumen. Such
high amounts of albumin promote proximal tubular cell
apoptosis.10–12 Flow cytometry of DNA content showed that
in our system, albumin increased the number of hypodiploid
apoptotic proximal tubular cells in a dose- and time-
dependent manner (Figures 4a–c). An increased rate of
apoptosis was already evident at 24 h and further increased
at 48 h of exposure to albumin (Figures 4a–c). Staining with
7-AAD/annexin V staining confirmed the increase in cell
death (Figure 4d).
Albumin induces a time-dependent increase in BASP1
mRNA and protein expression in tubular cells. We
examined the influence of albumin on BASP1 expression in
tubular cells. At concentrations that promoted tubular cell
apoptosis, albumin increased BASP1 mRNA (Figure 5a) and
protein (Figures 5b and c) expression in a time-dependent
manner. BASP1 expression was also increased by the lethal
combination of proinflammatory cytokines TWEAK/TNF/
interferon-γ (INF-γ).23 Confocal microscopy localized the
increased BASP1 expression in albumin-treated cells mainly
to the perinuclear area. A peripheral location near the cell
membrane was more conspicuous in albumin-treated apop-
totic cells, where it colocalized with actin (Figure 5d). This is
consistent with the peripheral localization of BASP1 in high-
glucose-exposed apoptotic tubular cells.19 The observation
that albumin increased BASP1 expression in tubular cells,
suggests that the increased tubular BASP1 expression
observed in vivo in proteinuric diseases may be a direct
manifestation of albumin cytotoxicity against tubular cells.
Inhibition of BASP1 expression protects against
albumin-induced apoptosis. To address the role of BASP1
in albumin-induced apoptosis, we used a siRNA approach.
Western blot and immunofluorescence confirmed efficient
gene silencing by BASP1-specific siRNA (Figure 6a,
Supplementary Figure 1). BASP1 targeting protected from
albumin-induced apoptosis quantified as percentage of
hypodiploid cells by flow cytometry of cell DNA content
(Figure 6b). Decreased cell death was also observed by
7-AAD/annexin V staining (Figure 6c). Morphological studies
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disclosed the presence of pyknotic nuclei characteristic of
apoptosis among cells exposed to albumin and protection of
albumin-exposed cells from apoptosis by BASP1 siRNA
(Figure 6d). By phase contrast microscopy, many detached,
small-sized floating cells were observed in cells exposed
to albumin (Figure 6e). This is consistent with the cell
detachment and fragmentation characteristic of apoptosis.17
Surviving cells exposed to albumin and treated with BASP1
siRNA looked healthy by contrast-phase microscopy
(Figure 6e). Albumin also increased Poly(ADP-ribose) poly-
merase (PARP) processing and caspase-3 activation and this
was decreased by BASP1 siRNA targeting (Figures 6f and g
and Supplementary figure 2). These results suggest that
BASP1 targeting protects from albumin-induced apoptosis.
BASP1 overexpression induces apoptosis in tubular
epithelial cells. We had previously observed that BASP1
overexpression promotes apoptosis in tubular epithelial cells.19
We have expanded this observation by assessing BASP1-
induced apoptosis by techniques not used in the previous
publication. Thus, overexpression of BASP1 increased the
percentage of apoptotic cells as assessed by flow cytometry
(Figure 7a). BASP1 overexpressing cells displayed PARP
processing and caspase-3 activation (Figure 7b).
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Figure 1 Tubular cell BASP1 expression is increased in rat nephrotic syndrome induced by PAN. (a) Systemic PAN administration resulted in nephrotic syndrome with severe
albuminuria (shown), which was fully established at day 10. At that time-point, other features of nephrotic syndrome were present such as hypercholesterolemia,
hypoalbuminemia and ascites (not shown). *Po0.02 versus control, **Po0.005 versus control. (b) Systemic PAN administration increased whole-kidney BASP1 mRNA
expression at day 2 and 10 as assessed by RT-qPCR. *Po0.05 versus control. (c) Systemic PAN administration increased whole-kidney BASP1 protein expression at day 2 and
10. Quantification and representative image of western blot of whole-kidney extracts. *Po0.001 versus control. (d) Immunohistochemistry with anti-BASP1 antibody localized
BASP1 to tubular cells at day 10 following PAN administration. Original magnification × 20
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Discussion
The main finding of this study is that BASP1 is an intracellular
mediator of albumin-induced tubular cell death. Tubular cell
BASP1 is upregulated in experimental and human proteinuric
kidney disease, supporting the clinical relevance of the
observation. Thus, we have provided functional evidence
supporting the concept that BASP1 is a novel therapeutic
target to protect tubular cells from the adverse effects of
excess albumin. This observation may lead to the develop-
ment of new therapeutic approaches to prevent CKD
progression in patients with persistent residual albuminuria
despite the prescription of current anti-proteinuric drugs.
BASP1 is a multifunctional protein that may behave as a
transcription factor, may have lipid raft and cytoskeletal
organizational properties, and may induce single channel
cation selective currents across negatively charged planar
lipid bilayers.24–27 In addition, BASP1 was recently character-
ized as a death promoter in tubular cells exposed to high
glucose concentrations, but not in apoptosis induced by a
combination of proinflammatory cytokines.19
BASP1 is expressed in kidney cells.25,19 Podocytes are
the main site of BASP1 expression in normal kidneys.25
In podocytes, BASP1 localizes to nuclei and regulates the
transcription factor activity of WT-1. By contrast, normal
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Figure 2 Colocalization of tubular cell BASP1 with TUNEL-positive cells in rat nephrotic syndrome induced by PAN. BASP1 immunofluorescence positive cells (green)
colocalized with cells stained with TUNEL (red) for fragmented DNA characteristic of apoptosis (arrows) at day 10. Original magnification × 20. Detail × 60
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Figure 3 Increased BASP1 expression in tubular cells in human nephrotic syndrome. BASP1 immunohistochemistry. (a) Minimal tubular BASP1 staining was observed in
control kidney tubules. (b) BASP1-positive tubular cells were observed in human nephrotic syndrome. Original magnification × 20
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Figure 4 Albumin induces apoptosis in human proximal tubular epithelial cells. Albumin-induced apoptosis in tubular cells was time- and dose-dependent. (a) Dose–response
at 24 h. *Po0.05 versus control. (b) Dose–response at 48 h. Cell death was assessed by flow cytometry of DNA content (hypodiploid cells suggestive of apoptosis). Note the
difference in scale between 24 h and 48 h data. Cells exposed to proinflammatory cytokines (100 ng/ml TWEAK, 30 ng/ml TNFα and INF-γ 30 U/ml –TTI-) for 48 h were used as a
positive control. *Po0.05 versus control, **Po0.02 versus control. (c) Representative images of DNA content flow cytometry results at 48 h. Note an increase in hypodiploid
apoptotic cells in albumin-treated cells (arrows). Mean±S.D. of three independent experiments. (d) Cell death was also assessed by flow cytometry following staining with
annexin V and 7-AAD after culture in the presence of albumin for 48 h. Representative experiment
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tubular cells express very low or undetectable amounts of
cytoplasmic BASP1. These differences in protein expression
and protein location are consistent with potentially diverse
roles of BASP1 in different cell types.
BASP1 is a member of the GAP-43, MARCKS and BASP1/
CAP-23 (GMC) family of functionally related proteins that
share an effector domain, acylation-mediated targeting
to the cell membrane and association with the cortical
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Figure 5 Albumin increases BASP1 expression in human proximal tubular epithelial cells. (a) Real-time RT-PCR analyses of BASP1 mRNA expression in cells cultured in the
presence of albumin (100 mg/ml). Mean±S.D. of four independent experiments. *Po0.005 versus control, **Po0.01 versus control. (b) Quantification of western blot results.
Cells were exposed to 100 mg/ml albumin. Mean±S.D. of four independent experiments. *Po0.03 versus control, **Po0.005 versus control. (c) Representative western blot of
BASP1. BASP1 expression was also increased by an apoptosis-inducing cytokine cocktail (100 ng/ml TWEAK, 30 ng/ml TNFα and INF-γ 30 U/ml). (d) Confocal microscopy
confirmed increased BASP1 (green) expression in cells exposed to albumin (100 mg/ml for 24 h). Colocalization of BASP1 was further explored in cells undergoing albumin-
induced apoptosis. BASP1 localized to the cell periphery in apoptotic cells with pyknotic nuclei (DAPI, blue), where it colocalized with phalloidin-stained actin (red) rings (arrow
and detail)
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cytoskeleton.26 A role in apoptosis has been suggested for
GAP-43 and Xenopus MARCKS-related protein in non-renal
cells.28–30 Enforced BASP1 overexpression induces apopto-
sis in tubular epithelium.19 Furthermore, endogenous BASP1
expression is increased by either a lack of survival factors or by
the presence of certain lethal stimuli such as high glucose or a
cytokine combination (TWEAK/TNFα/INF-γ).19 Albumin is a
novel, pathophysiologically relevant stimulus that promotes
tubular cell apoptosis, BASP1 upregulation and BASP1
redistribution to the cell cortex in apoptotic cells, where
BASP1 colocalizes with the apoptotic actin ring of apoptotic
cells. In addition to being pathophysiologically relevant,
albuminuria is the current standard to assess CKD progres-
sion risk in the clinic.2 Thus, albuminuria is quantified in CKD
patients during routine clinical care. This allows the easy
identification in daily clinical practice of patients that might
benefit from nephroprotective strategies that protect tubular
cells from the adverse effects of albumin. In this regard, siRNA
targeting of BASP1 protected tubular cells from albumin-
induced apoptosis. The present report does not explore the
molecular mechanisms of BASP1 promotion of apoptosis,
because in tubular cells, BASP1-induced apoptosis was
already shown to be prevented by Bax antagonists and
caspase inhibitors, suggesting that BASP1 has a role
upstream of mitochondrial injury and caspase activation. By
contrast to the requirement for BASP1 for tubular cell
apoptosis induced by albumin, cytokine (TWEAK/TNFα/INF-
γ)-induced apoptosis did not require BASP1.19 Interestingly,
cytokine-induced tubular cell apoptosis was recently shown to
have also features of necroptosis.31
Increased tubular BASP1 expression was observed in non-
diabetic human and experimental albuminuric nephropathies.
This suggests that the increased tubular BASP1 previously
observed in diabetic nephropathy, which is also an albuminuric
nephropathy, cannot be solely attributed to high glucose
levels.19 Thus, increased tubular BASP1 is also observed
when albuminuria is present and glucose levels are normal. In
this regard, according to the Kidney & Urinary Pathway
Knowledge Base (KUPKB, www.kupkb.org; accessed 25
February 2014), BASP1 protein is increased in urine from
patients with type 2 diabetes with microalbuminuria as
compared with those with normoalbuminuria,32 despite both
groups displaying high glucose levels. These findings are
consistent with a role of albumin as an inducer of tubular cell
BASP1 expression in vivo. Moreover, data collected in the
Nephromine database showed that in 21 patients with
membranous nephropathy (eGFR 85±40ml/min/1.73 m2,
age 54±18 years, 12 males/9 females), tubulointerstitial
BASP1 mRNA expression was found to be 1.204-fold
(P= 0.012) that of healthy living kidney donors. For compar-
ison, non-proteinuric conditions such as thin basement
membrane disease (fold-change 1.068) and tumor nephrect-
omy (fold-change −1.042) did not significantly differ from
healthy living kidney donors. (http://www.nephromine.org/;
accessed 2 June 2014).33
In rat nephrotic syndrome, BASP1 protein expression
increased to a higher degree that mRNA expression.
Discrepancies between mRNA and protein expression are
not unusual. There are several potential explanations for this
observation. The peak mRNA expression may have occurred
at an earlier time point. Alternatively, BASP1 protein half-life
may be increased. In this regard, posttranslational modifica-
tions of BASP1 may underlie differences in location, function
and, possibly, half-life. BASP1 may undergo a series of
posttranslational modifications such asmyristoylation, sumoy-
lation, caspase-dependent processing or other proteolytic
processes.34–37 The transcription factor function of BASP1 is
regulated by sumoylation34 andmyristoylation.35 AnN-terminally
myristoylated form of BASP1 regulates actin cytoskeleton
dynamics in neurons. In neurons, BASP1 is localized
mainly in the lipid rafts of synaptic vesicles and plasma
membranes, where it could participate in the transport and
anchoring of glutamic acid decarboxylase isoforms (GAD)
GAD65 and GAD67.20 More in line with the current report,
recent data have linked BASP1 to tumor suppression.38–40
The proapoptotic role of BASP1 might contribute to tumor
suppression, although this possibility has not been formally
explored. Increased BASP1 expression has also been
observed in other inflammatory conditions, although the role
of BASP1 in these conditions was not explored. Thus, gene
expression profiling studies disclosed increased BASP1
expression in human dermatitis herpetiformis41 and in goat
mammary glands infected with S. aureus.42 A better grasp of
the determinants of BASP1 intracellular localization and
function may contribute to the design of BASP1-targeting
therapies. The unique localization and set of transporters of
proximal tubular cells may be advantageous to design
therapies specifically targeting these cells.43–45 Thus, we
may take advantage of the albumin overload of proximal
tubular cells in proteinuric states and their capacity to recover
molecules from the glomerular ultrafiltrate, as well as of the
high blood flow of the kidneys (one-fourth of the heart
output by volume) and the magnitude of glomerular filtration
(over 100ml/min) to target anti-BASP1 molecules specifically
to tubular cells.
The data presented in this study clearly show that
exposure to albumin, as may occur in vivo in proteinuric
nephropathies, increases BASP1 expression and pro-
motes BASP1-dependent tubular cell apoptosis. This
information may be used to design novel therapeutic
approaches that slow CKD progression by protecting
tubular cells from the adverse consequences of albumi-
nuria in patients not fully responding to current anti-
proteinuric agents. These novel approaches may include
interfering with BASP1 function in tubular epithelium by
using specific siRNAs.
Materials and Methods
Cell culture and reagents. HK-2 human proximal tubular epithelial cells
(ATCC, Rockville, MD, USA) were grown on RPMI 1640 (Life Technologies, Grand
Island, NY, USA) with 10% heat-inactivated FBS, 2 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml
sodium selenite and 5 ng/ml hydrocortisone in 5% carbon dioxide at 37 °C. For
experiments, cells were cultured in serum-free media 24 h prior to addition of stimuli
and throughout the experiment. Exposure of cultured tubular cells to bovine serum
albumin (Sigma, St. Louis, MO, USA) was used as a surrogate for the in vivo
exposure of tubular cells to albumin in proteinuric nephropathies. Recombinant
human soluble TWEAK (Millipore, Billerica, MA, USA) was used at 100 ng/ml,
murine TNF-α (PrePotech, London, UK) at 30 ng/ml and INF-γ (PrePotech, London,
UK) at 30 U/ml.
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Cell death and apoptosis. Cells were cultured to subconfluence in 12-well
plates. Apoptosis was assessed by flow cytometry of DNA content and nuclear
morphology. For assessment of apoptosis, adherent cells were pooled with
spontaneously detached cells, and stained in 100 μg/ml propidium iodide, 0.05%
NP-40, 10 μg/ml RNAse A in PBS at 4 °C for 41 h. This assay permeabilizes the
cells. Permeabilization allows entry of propidium iodide into all cells, dead or alive.
Apoptotic cells are characterized by a lower DNA content (hypodiploid cells) because
of nuclear fragmentation. Thus, this assay is not based on the known ability of
propidium iodide to enter dead cells. The percentage of apoptotic cells with decreased
DNA content (Ao) was counted by flow cytometry using BD CellQuest Software (BD
Biosciences, San Diego, CA, USA).46 As a positive control, apoptosis was induced
by exposure to a lethal cytokine cocktail (30 ng/ml TNFα, 100 ng/ml TWEAK and
30 UI/ml INF-γ) for 48 h. Nuclei of formalin-fixed cells were stained with DAPI (Sigma)
to observe the typical morphological changes, as previously described.19,46
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The PE Annexin V Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA,
USA) was used to assess both apoptosis and necrosis by flow cytometry. This
method discriminates between early apoptotic (7-AAD-negative, annexinV-positive),
and late apoptotic or necrotic cells (7-AAD-positive, annexinV-positive).
Western blot analysis. Tissue and cell samples were homogenized in lysis
buffer,47 then separated by 10 or 12% SDS-PAGE under reducing conditions and
transferred to PVDF membranes (Millipore, Bedford, MA, USA), blocked with 5%
skimmed milk in PBS/0.5% v/v Tween 20 for 1 h, and washed with PBS/Tween.
Primary antibody was goat polyclonal anti-BASP1 (1 : 500, Santa Cruz, Santa Cruz,
CA, USA), rabbit polyclonal anti-cleaved caspase-3 (1 : 1000; Cell Signaling,
Hertfordshire, UK), rabbit monoclonal anti-cleaved PARP (1 : 1000, Abcam,
Cambridge, UK), mouse anti-tubulin monoclonal antibody (1 : 5000, Sigma) or
mouse GAPDH (Millipore, Billerica) followed by incubation with horseradish
peroxidase-conjugated secondary antibody (1 : 2000, Amersham, Aylesbury, UK).
Blots were developed with the enhanced chemiluminescence method following the
manufacturer’s instructions (Amersham). Levels of expression were corrected for
minor differences in loading.
Quantitative reverse transcription-polymerase chain reaction.
One microgram RNA isolated by Trizol (Invitrogen, Paisley, UK) was reverse-
transcribed with High Capacity cDNA Archive Kit and real-time PCR was performed
on a ABI Prism 7500 PCR system (Applied Biosystems, Foster City, CA, USA) using
the DeltaDelta Ct method.46 Expression levels are given as ratios to GAPDH. Pre-
developed primer and probe assays were from Applied Biosystems.
Transient transfection. For transient transfection, cells were plated at a
density of 8 × 104 cells/plate in six-well plates (Costar, Cambridge, MA, USA) with
RPMI 1640 (10% FBS) 24 h before transfection. Cells were transfected with 5 μg of
BASP1 containing plasmid or empty vector (pcDNA3) using FuGENE 6 (Roche,
Indianapolis, IN, USA) according to the manufacturer's protocol. Real-time RT-PCR
analyses of BASP1 mRNA in cells transfected with BASP1 confirmed a 300-fold
BASP1 overexpression.19
Transfection of small-interfering RNA. Cells were grown in six-well
plates (Costar) and transfected with a mixture of 20 nmol/ml BASP1 siRNA
(Ambion, Applied Biosystems), Opti-MEM I Reduced Serum Medium and siPORT
Amine Transfection Agent (Ambion, Applied Biosystems).19 After 18 h, cells were
washed and cultured for 48 h in complete medium and serum-depleted for 24–48 h
before stimulation. These time points were selected from a time-course of BASP1
protein expression in response to siRNA. A negative control scrambled siRNA
provided by the manufacturer did not reduce BASP1 protein.
Confocal microscopy. Cells plated onto Labtek slides (Nunc, Naperville, IL,
USA) were fixed in 4% paraformaldehyde and permeabilized in 0.2% Triton X-100 in
PBS for 10 min each. After washing in PBS, cells were incubated overnight at 4 °C
with rabbit polyclonal anti-BASP1 antibody (1 : 100, Abcam), followed by incubation
with anti-rabbit Alexa Fluor 488 (1 : 300, Invitrogen). After washing, cells were
mounted in 70% glycerol in PBS, and analyzed with a DM-IRB confocal microscope
(Leica DM, Bannockburn, IL, USA).46 F-actin was stained with 800 μM TRITC-
phalloidin (Sigma) in the dark for 30 min at room temperature. Apoptosis was
characterized by morphologic and functional criteria. Nuclei cells were stained with
Albumin Control BASP1 siRNA +Albumin BASP1 siRNA 
Control Albumin BASP1 siRNA BASP1 siRNA+Albumin 
Cleaved PARP 
GAPDH 
BSA                0             0             50            0            50               mg/ml 
Scramble siRNA BASP1 siRNA 
Scramble siRNA 
Cleaved Caspase-3 
GAPDH 
BASP1 siRNA 
BSA 0 0   25  50 0 0 25  50  mg/ml
Figure 6 (Continued)
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DAPI (Vector Laboratories, Inc., Burlingame, CA, USA) to observe the typical
morphological changes.
Animal model. Two groups of 10-week-old Wistar Kyoto rats (Criffa, Barcelona,
Spain) were studied (n= 9/group). Nephrotic syndrome was induced by a single i.v.
injection of 150 mg/kg PAN (Sigma).48 Control rats received vehicle (Saline). Rats
were killed at day 2 and day 10 after PAN injection following a 24 h urine collection
in metabolic cages. Kidneys were perfused in situ with cold saline before removal.
One kidney from each rat was fixed in buffered formalin, embedded in paraffin and
used for immunohistochemistry. The other kidney was snap-frozen in liquid nitrogen
for RNA and protein studies. Albuminuria was determined by ELISA, using rat
albumin as a standard (Celltrend, Luckenwalde, Germany). All studies were
performed in accordance with the European Union normative.
Immunohistochemistry and immunofluorescence. Kidney samples
were obtained from the IIS-FJD Biobank (Madrid, Spain). Samples were obtained by
percutaneous renal biopsy from patients undergoing diagnostic evaluation for
proteinuric nephropathy at the Division of Nephrology (IIS-FJD) that donated for
research the remnant tissue following diagnostic evaluation. Kidney biopsy samples
from six patients with a diagnosis of membranous nephropathy were studied. Age
(mean± S.D.) 61± 4, sex 3 male/3 female, creatinine 2.1± 0.9 mg/dl, albuminuria
4897± 330 mg/g creatinine, HbA1C levelo6.0%. Control human kidney specimens
were taken from normal portions of renal tissue from patients who underwent
surgery because of localized renal tumors. Immunohistochemistry was carried out in
paraffin-embedded tissue sections of 5 μm thickness as previously described.19
Primary antibody was rabbit polyclonal anti-BASP1 (1 : 50, Abcam). Sections were
counterstained with Carazzi's hematoxylin. Negative controls included incubation
with a non-specific immunoglobulin of the same isotype as the primary antibody.
The local Ethics Committee approved the study protocol and informed consent was
obtained. Rat tissue immunohistochemistry was performed as described for human
tissue.
To correlate apoptosis with BASP1 expression in rat kidney, a double-labeling
immunoflurescence was used. Apoptosis was assayed by deoxynucleotidyl-
transferase-mediated dUTP nick-end labeling (In Situ Cell Death Detection Kit;
Roche) according to the manufacturer’s instructions. Next, anti-BASP1 (1 : 100,
Abcam) was added followed by Alexa-488-conjugated secondary antibody as
previously described.47
Statistics. Data are expressed as mean± standard error of media. Mann-
Whitney, two-sided t-test or one-way ANOVA were applied to assess differences
between groups. A P-value o0.05 was considered statistically significant.
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